9 completed, 1 active not recruiting, 1 not yet recruiting, 1 unknown. 4 Phase 4, 3 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 3, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 3 | Completed 3 |
| Early Phase 1 | 1 | Completed 1 |
Follow this condition Literature Review of Ocular Pain trials Research Report on Ocular Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain acoltremon ophthalmic solution 0.003% - Ocular Pain, Dry Eye | Phase 4 | Not yet recruiting | University of South Florida | 28 | 2026-10-01 | 2026-10-06 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers BL1332 ophthalmic solution, BL1332 ophthalmic vehicle - Ocular Pain | Phase 1 | Active not recruiting | Bausch & Lomb Incorporated | 24 | 2025-07-29 | 2026-01-27 |
| Validation of Ocular Pain Questionnaire: Single-center, Prospective Observational Study Ocular Pain, OSDI | Unknown | IRCCS Ospedale San Raffaele | 333 | 2024-11-01 | 2024-10-24 | |
| Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure TetraLens bandage contact lens, Control Acuvue Oasys Bandage contact Lens - Ocular Pain | Early Phase 1 | Completed | Vance Thompson Vision | 10 | 2023-06-26 | 2025-09-17 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 50 | 2023-06-01 | 2026-02-20 |
| A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert - Anterior Chamber Inflammation, Ocular Pain | Completed | Nicole Fram M.D. | 25 | 2021-03-09 | 2021-07-26 | |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 36 | 2020-10-16 | 2023-07-24 |
| Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. PRO-155, Placebo - Pterygium, Ocular Pain | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 166 | 2017-12-13 | 2019-11-20 |
| Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 2 | Completed | Sylentis, S.A. | 66 | 2015-06-01 | 2016-04-05 |
| RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1% - Corneal Endothelial Cell Loss, Ocular Pain | Phase 2 | Completed | Biogen | 307 | 2014-05-31 | 2025-06-03 |
| Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Sylentis, S.A. | 60 | 2012-11-01 | 2015-05-25 |
| Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers SYL1001 - Ocular Pain, Dry Eye | Phase 1 | Completed | Sylentis, S.A. | 30 | 2011-07-01 | 2012-07-17 |
Eye Pain (12) · Dry Eye Syndromes (4) · Corneal Edema (3) · Corneal Endothelial Cell Loss (1) · Macular Edema (1) · Pterygium (1)
Eye Diseases (12) · Eye Manifestations (12) · Neurologic Manifestations (12) · Pain (12) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Corneal Diseases (4) · Lacrimal Apparatus Diseases (4) · Conjunctival Diseases (1) · Macular Degeneration (1) · Pathologic Processes (1) · Postoperative Complications (1) · Retinal Degeneration (1) · Retinal Diseases (1)
Calcium Dobesilate (3) · Dexamethasone (2) · bromfenac (2) · prednisolone acetate (2) · Methylprednisolone (1) · Ophthalmic Solutions (1)
Nicole Fram M.D. (3) · Sylentis, S.A. (3) · Bausch & Lomb Incorporated (1) · Biogen (1) · IRCCS Ospedale San Raffaele (1) · Laboratorios Sophia S.A de C.V. (1) · University of South Florida (1) · Vance Thompson Vision (1)
United States (7) · Spain (3) · Estonia (1) · Mexico (1)
Nicole R Fram, M.D. (2) · Belen Sadaba, MD, PhD (1) · Nicole Fram, MD (1) · Pedram Hamrah, MD (1) · Vance Thompson, MD (1)